A study to evaluate the risk of de novo hepatocellular carcinoma in patients with compensated cirrhosis treated with direct-acting antivirals for chronic hepatitis C (De Novo DAA PASS)

First published 05/05/2020

Last updated 14/03/2024

EU PAS number:

EUPAS30818

Study

Finalised

Documents

Study protocol

Initial protocol

denovo-daa-pass-protocol_v3_abstract_01Aug2019

English (158.39 KB - PDF)View document

Updated protocol

denovo-daa-pass-protocol_v3_redacted

First published: 22/02/2024

English (328.84 KB - PDF)View document

Study results

b20146-abstract

English (185.62 KB - PDF)View document

Study report

Other information

ENCePP Seal

ENCePP Seal documents

Secondary tabs